ADHD

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

What is new in research on ADHD?

Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.

Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!

Researchers performed a double-blind, placebo-controlled pilot study of solriamfetol.

From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

What is the impact of ADHD on sleep? Researchers performed a systematic review and meta-analysis of objectively measured sleep in children and adolescents with ADHD.

What is new in research on TMS?

Positive results were just released from 2 phase 3 clinical trials evaluating centanafadine for the treatment of adolescents and children with ADHD.

Is adult ADHD validated by research? These authors think not.

The FDA has released a draft guide to offer their perspective and thoughts on the development of treatments for stimulant use disorder.

ADHD in adults lead to educational, occupational, relational, and judgment impairments.

The experts weighed in on a wide variety of psychiatric issues for the September 2023 issue of Psychiatric Times.

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

"The history of psychiatry is a history of fads in theory, diagnosis, and treatment. Such rapid shifts in conceptualization—such as the emergence of the concept of adult ADHD—almost always warrant informed critical examination."

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

What is new in research on attention-deficit/hyperactivity disorder?

The study explored the intervention’s effects using both quantitative and qualitative methods.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.

Generics are now approved for adults in the treatment of BED and for individuals aged 6 years and older in the treatment of ADHD.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023. As these shortages continue, here's how you can best support your patients with ADHD.

In this CME article, learn more about the full continuum of presentations and variable trajectories typical of females with ADHD.

From an examination of the fentanyl epidemic to the connection between ADHD medication and height, here are highlights from the week in Psychiatric Times.

Doctor, how will this medication affect my child’s growth? Researchers performed a register-based study of ADHD, ADHD medication, and height.

From obesity and metabolism in first-episode MDD to psychiatrist liability and suicide, here are highlights from the week in Psychiatric Times.

New positive data was recently released from 5 in vitro studies investigating the potential for drug-drug interaction of mazindol.

Data showed good news for safety and tolerability with mixed good news for efficacy.

From adherence in addiction recovery treatment to the relationship between social media use and youth mental health, here are highlights from the week in Psychiatric Times.

Where might proponents of neurodiversity and psychiatrists agree?